INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Entry into a Material Definitive Agreement

0

INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Incyte Corporation (the “Company”) entered into a letter agreement, dated February 17, 2017 (the “Baker Exchange Agreement”) with certain entities (the “Baker Entities”) affiliated with Julian C. Baker, a director of the Company, to which the Baker Entities agreed to exchange $259,000,000 in aggregate principal amount of the Company’s 0.375% Convertible Senior Notes due 2018 (the “2018 Notes”) and $274,500,000 in aggregate principal amount of the Company’s 1.25% Convertible Senior Notes due 2020 (the “2020 Notes” and, together with the 2018 Notes, the “Notes”) for an aggregate of 10,610,782 shares of the Company’s common stock, $.001 par value per share (“Common Stock”). The shares of Common Stock to be issued in exchange for the Notes represent the number of shares into which the Notes were convertible together with an additional negotiated number of shares. The description of the Baker Exchange Agreement in this report is a summary and is qualified in its entirety by the terms of the Baker Exchange Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

On February 17, 2017, the Company entered into separately negotiated agreements (the “Exchange Agreements”) with a limited number of holders of the 2018 Notes and the 2020 Notes to which such holders agreed to exchange $86,764,000 in aggregate principal amount of 2018 Notes and $73,724,000 in aggregate principal amount of 2020 Notes for the shares of Common Stock into which such Notes were convertible, aggregating 3,100,708 shares, and an aggregate of 25,074 additional shares of Common Stock and approximately $7.5 million in cash.

The issuances of the shares of Common Stock in exchange for the Notes to the Baker Exchange Agreement and the Exchange Agreements are being made in reliance on the exemption from the registration requirements of the Securities Act of 1933 to Section 3(a)(9) thereof. The Company expects to complete the exchanges to the Baker Exchange Agreement and the Exchange Agreements during the week of February 20, 2017. Additional information pertaining to the shares of Common Stock issuable to the Baker Exchange Agreement is set forth in Item 1.01 hereof and incorporated herein by reference.

Forward-Looking Statements

The statement above with respect to the anticipated timing of the completion of the exchanges is a forward-looking statement within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. This forward-looking statement is subject to risks and uncertainties that may cause actual results to differ materially, including the satisfaction of customary closing conditions and logistics involved in the delivery of the securities being exchanged. The Company disclaims any intent or obligation to update this forward-looking statement except to the extent required by law or regulations.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

10.1 Letter Agreement dated February 17, 2017 among Incyte Corporation and the entities named therein.


About INCYTE CORPORATION (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company’s second oral JAK1 and JAK2 inhibitor is baricitinib.

INCYTE CORPORATION (NASDAQ:INCY) Recent Trading Information

INCYTE CORPORATION (NASDAQ:INCY) closed its last trading session up +0.31 at 120.49 with 941,388 shares trading hands.